Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Invested Capital (2022 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Return on Invested Capital for 4 consecutive years, with 1.28% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Invested Capital rose 1414.0% to 1.28% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.28%, a 1414.0% increase, with the full-year FY2025 number at 2.27%, up 48.0% from a year prior.
  • Return on Invested Capital was 1.28% for Q4 2025 at Rhythm Pharmaceuticals, up from 2.55% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.76% in Q1 2022 to a low of 28.61% in Q2 2025.
  • A 4-year average of 7.55% and a median of 3.92% in 2024 define the central range for Return on Invested Capital.
  • Biggest YoY gain for Return on Invested Capital was 1414bps in 2025; the steepest drop was -2332bps in 2025.
  • Rhythm Pharmaceuticals' Return on Invested Capital stood at 0.76% in 2022, then dropped by -23bps to 0.93% in 2023, then plummeted by -1561bps to 15.42% in 2024, then soared by 92bps to 1.28% in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Return on Invested Capital are 1.28% (Q4 2025), 2.55% (Q3 2025), and 28.61% (Q2 2025).